Loading…
Assembly Biosciences, Inc. is projected to rise to $30.00 by 2027, a +9% move from its current price of $27.40. ASMB is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $26.60 | $27.40 | $28.23 | +0.01% |
| May 30 | $26.27 | $27.41 | $28.59 | +0.03% |
| May 31 | $26.03 | $27.41 | $28.87 | +0.04% |
| Jun 1 | $25.83 | $27.42 | $29.10 | +0.06% |
| Jun 2 | $25.65 | $27.42 | $29.31 | +0.07% |
| Jun 3 | $25.49 | $27.42 | $29.51 | +0.09% |
| Jun 4 | $25.35 | $27.43 | $29.68 | +0.10% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $25.35 | $27.43 | $29.68 | +0.10% |
| Week 2 | $24.55 | $27.46 | $30.70 | +0.21% |
| Week 3 | $23.97 | $27.49 | $31.52 | +0.31% |
| Week 4 | $23.49 | $27.52 | $32.22 | +0.42% |
| Week 5 | $23.08 | $27.54 | $32.87 | +0.53% |
| Week 6 | $22.72 | $27.57 | $33.46 | +0.63% |
| Week 7 | $22.40 | $27.60 | $34.02 | +0.74% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Assembly Biosciences, Inc. is a biotechnology company that develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are in Phase 1 clinical studies for recurrent genital herpes; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study for the treatment of chronic hepatitis delta virus (HDV) infection.
The company also develops ABI-4334, an orally bioavailable next generation capsid assembly modulator that is in Phase 1b study clinical trial for the treatment of chronic hepatitis B virus (HBV) infection; and ABI-7272, an oral broad-spectrum NNPI for the treatment of transplant-associated herpesviruses. It has an option, license, and collaboration agreement with Gilead Sciences, Inc. for the research and development of virology therapies.
The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.
Assembly Biosciences, Inc. (ASMB) is currently priced at $28.34 per share, has a market cap of $450.4M, and ranks 3119. The near-term forecast shows gradual upside, with the 2026 average price at $28.34, rising to $30.95 in 2027 and $33.55 in 2028, according to the projections.
The longer-term forecast indicates meaningful upside, with the 2030 average at $45.66 and the 2050 average at $234.43, while max projections extend toward $67.86 in 2030 and $448.59 by 2050. These figures imply substantial long-run upside but remain subject to uncertainty and market conditions.
A major floor 16.1% below — a decisive break under it would weaken the trend.
The nearest floor, 4.2% below — buyers have tended to step in here.
The nearest ceiling, 15.8% above — a clean break opens room to run.
A major ceiling 23.8% above — clearing it would confirm fresh momentum.
Key ASMB support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ASMB market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $27.45 | Sell | $27.79 | Sell |
| MA 10 | $28.19 | Sell | $28.07 | Sell |
| MA 20 | $28.66 | Sell | $28.37 | Sell |
| MA 50 | $28.53 | Sell | $28.60 | Sell |
| MA 100 | $28.58 | Sell | $28.68 | Sell |
| MA 200 | $28.98 | Sell | $27.21 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 45.41 | Neutral |
| Stoch RSI (14) | 26.64 | Neutral |
| CCI (20) | -53.49 | Neutral |
| Williams %R (14) | -79.12 | Info |
| MACD (12,26,9) | -0.20 | Sell |
| ROC (12) | -7.87 | Sell |
| Bollinger %B (20,2) | 0.32 | Neutral |
| Stochastic %K (14) | 20.88 | Neutral |
| TRIX (15) | -0.02 | Sell |
| Awesome (5,34) | -1.15 | Sell |
| Ultimate (7,14,28) | 39.30 | Neutral |
| Momentum (10) | -3.42 | Sell |
| Aroon Osc (25) | -20.00 | Sell |
| Hull MA (9) | 27.92 | Sell |
| ADX (14) | 12.34 | Neutral |
| ATR (14) | 0.88 | Info |
Sentiment is NEUTRAL. The RSI14 is 50, and the 50-day simple moving average is $28.55 while the 200-day simple moving average is $28.92. Support sits at $26.26 and resistance at $31.72. The 30-day price range runs from $23.28 to $34.49, signaling a broad near-term trading band. Annualized volatility is 60%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $25.39 | $27.40 | $36.80 | 0% | Neutral | |
| $23.58 | $30.00 | $40.56 | +9% | Neutral | |
| $24.70 | $32.39 | $45.51 | +18% | Neutral | |
| $29.11 | $39.14 | $56.70 | +43% | Bullish | |
| $32.32 | $44.44 | $66.05 | +62% | Bullish | |
| $38.51 | $54.04 | $82.15 | +97% | Bullish | |
| $42.70 | $61.09 | $94.75 | +123% | Bullish | |
| $39.72 | $57.85 | $91.37 | +111% | Bullish | |
| $42.04 | $62.30 | $100.06 | +127% | Bullish | |
| $44.96 | $67.74 | $110.51 | +147% | Bullish | |
| $67.54 | $109.71 | $191.06 | +300% | Bullish | |
| $124.31 | $230.29 | $440.95 | +740% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $25.39 | $27.40 | $32.28 | +0.00% |
| June 2026 | $23.28 | $27.40 | $33.05 | +0.01% |
| July 2026 | $23.39 | $27.78 | $34.00 | +1.37% |
| August 2026 | $24.11 | $28.84 | $35.71 | +3.84% |
| September 2026 | $23.86 | $28.71 | $35.87 | -0.47% |
| October 2026 | $23.02 | $27.85 | $35.09 | -2.98% |
| November 2026 | $23.19 | $28.20 | $35.78 | +1.23% |
| December 2026 | $23.58 | $28.81 | $36.80 | +2.17% |
Click any year to see its month-by-month ASMB forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect ASMB to range from $25.39 to $36.80 through 2026. The $27.40 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The ASMB price prediction for 2027 points to an average of $30.00 (low $23.58, high $40.56) — a potential gain of +9% on today's $27.40. A consolidation phase looks the most probable path here.
In 2028, ASMB is projected to trade between $24.70 and $45.51, averaging $32.39 — a potential gain of +18% from today's $27.40. That is up +8% on the projected 2027 average. Price action looks broadly range-bound.
Assembly Biosciences, Inc.'s 2029 outlook centres on $39.14, within a $29.11 to $56.70 range. That is up +21% on the projected 2028 average. That marks a +43% change versus current levels. Buyers look set to stay in control over this stretch.
By 2030, ASMB could reach as high as $66.05, with a base case around $44.44 and support toward $32.32 — roughly +62% from $27.40. Momentum favours further upside here.
Expect ASMB to range from $38.51 to $82.15 through 2031. The $54.04 average target implies a +97% move from current prices. That is up +22% on the projected 2030 average. Buyers look set to stay in control over this stretch.
The ASMB price prediction for 2032 points to an average of $61.09 (low $42.70, high $94.75) — a potential gain of +123% on today's $27.40. Momentum favours further upside here.
In 2033, ASMB is projected to trade between $39.72 and $91.37, averaging $57.85 — a potential gain of +111% from today's $27.40. That is -5% versus the projected 2032 average. Buyers look set to stay in control over this stretch.
Assembly Biosciences, Inc.'s 2034 outlook centres on $62.30, within a $42.04 to $100.06 range. That is up +8% on the projected 2033 average. That marks a +127% change versus current levels. Momentum favours further upside here.
By 2035, ASMB could reach as high as $110.51, with a base case around $67.74 and support toward $44.96 — roughly +147% from $27.40. Buyers look set to stay in control over this stretch.
Expect ASMB to range from $67.54 to $191.06 through 2040. The $109.71 average target implies a +300% move from current prices. That is up +62% on the projected 2035 average. Momentum favours further upside here.
The ASMB price prediction for 2050 points to an average of $230.29 (low $124.31, high $440.95) — a potential gain of +740% on today's $27.40. Buyers look set to stay in control over this stretch.
Investing $1,000 in ASMB today (≈ 36.49635 ASMB) could be worth
$8,404.89
+$7,404.89 (+740%) by 2050 · US Dollar
Based on the average projected ASMB price of $230.29 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ASMBwould be worth at today's price.
$1,000 invested in ASMB on May 27, 2025 (≈ 70.921984 ASMB) would be worth
$1,943.26
+$943.26 (+94.3%) today · 1.94× · US Dollar
Based on a ASMB entry price of $14.1 vs. today's $27.4.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $26.26 | $1,043.41 | +4.3% |
| 1 month ago | $27.52 | $995.64 | -0.4% |
| 3 months ago | $29.59 | $925.99 | -7.4% |
| 6 months ago | $37.79 | $725.06 | -27.5% |
| 1 year ago | $14.1 | $1,943.26 | +94.3% |
| All time (5.0y) ago | $48.36 | $566.58 | -43.3% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ASMB forecast.
Our base-case forecast reaches $55.00 around 2032.
Implied market cap at $55.00: $1.09B
The multi-year forecast shifts toward a BULLISH stance beginning in 2029, with 2029’s average price at $40.22 and a 41.9% ROI. By 2030, the average is $45.66 with a 61.1% ROI, and 2031 at $55.88 with a 97.2% ROI, followed by 2032 at $62.68 with a 121.2% ROI. The path continues with 2033 at $59.01 (108.2%), 2034 at $64.22 (126.6%), and 2035 at $69.54 (145.4%).
By 2040 the average reaches $112.84 with a 298.1% ROI, and by 2050 the average is $234.43 with a 727.2% ROI. These are projected outcomes and not guarantees; actual results depend on market conditions and other factors.
Tap a question to reveal the answer.
The 2030 forecast average price is $45.66, with a min of $33.21 and a max of $67.86; ROI 61.1%; sentiment BULLISH.
Forecasts show a progression from NEUTRAL in 2026-2028 to BULLISH from 2029 onward, with 2030-2050 averages rising to $45.66, $112.84, and $234.43 respectively and ROIs up to 727.2% by 2050. These are estimates and not guarantees.
Yes, the maximums in the forecast reach $196.41 by 2040 and $448.59 by 2050, while the 2030 max is $67.86.
Current price is $28.34 and market cap is $450.4M.
The 2050 forecast shows an average price of $234.43, a minimum of $126.67, a maximum of $448.59, and a ROI of 727.2%, with sentiment BULLISH.
Assembly Biosciences, Inc. Community Discussion
0Share your Assembly Biosciences, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.